Is Sermorelin Legal in Florida? How to Access It Legally

What Sermorelin Is and Why Its Legal Status Differs From Other Peptides

Sermorelin is a 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to secrete the patient's own growth hormone rather than introducing exogenous recombinant GH. That mechanism of action is directly relevant to legality because synthetic recombinant human growth hormone (somatropin) is a Schedule III controlled substance under 21 U.S.C. § 333(e), restricted to narrow indications. Sermorelin is not somatropin and carries no equivalent scheduling.

Sermorelin's Pharmaceutical History

The FDA approved Sermorelin acetate (brand name Geref) for diagnostic and therapeutic use in pediatric GH deficiency in 1990 [1]. Sercel Therapeutics voluntarily withdrew Geref from the US market in 2008 for business reasons, not for safety or efficacy concerns [2]. That withdrawal is the source of ongoing confusion: the drug is no longer commercially manufactured, yet it remains compoundable precisely because it was an approved drug and is not listed as a substance that may not be compounded.

Why Discontinuation Does Not Equal Illegality

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product that is not commercially available if a licensed practitioner provides a valid prescription for an identified patient [3]. The FDA's Memorandum on Withdrawn Drugs clarifies that voluntary market withdrawal does not automatically bar compounding. Sermorelin does not appear on the FDA's lists of drugs withdrawn for safety or efficacy reasons, which is the specific list that would prohibit 503A compounding [4].

The Federal Regulatory Framework Governing Sermorelin Compounding

503A: Patient-Specific Compounding

Section 503A of the FD&C Act covers traditional compounding pharmacies [3]. To dispense Sermorelin lawfully under 503A, the pharmacy must:

• Hold a valid state pharmacy license in Florida (or the patient's state for interstate shipment)
• Compound only in response to a valid prescription for an individual patient
• Not compound commercially in advance of receiving prescriptions
• Source bulk active pharmaceutical ingredient (API) from an FDA-registered supplier
• Comply with USP Chapter 797 sterile compounding standards for injectable preparations [5]

503A pharmacies do not register with the FDA, but they are subject to FDA inspection and must not appear on the agency's warning-letter list.

503B: Outsourcing Facilities

Section 503B outsourcing facilities are FDA-registered and may produce sterile compounded drugs in larger quantities without patient-specific prescriptions, supplying licensed practitioners directly [6]. Several 503B facilities compound Sermorelin for physician offices and telehealth platforms. Patients receiving Sermorelin dispensed through a 503B facility still require a valid prescription, but the pharmacy may produce the compound in anticipation of prescriptions rather than one-at-a-time.

The Bulk Substances Lists

The FDA maintains three lists relevant to compounding:

1. The 503A Bulks List (drugs that may be compounded from bulk API under 503A) [7]
2. The 503B Bulks List (drugs permitted in bulk for outsourcing facilities) [8]
3. The "Do Not Compound" list (drugs withdrawn for safety or efficacy reasons) [4]

Sermorelin is not explicitly named on the affirmative 503A bulks list. However, the FDA's policy for Section 503A is that bulk substances not on a negative list retain a provisional compounding pathway while the agency works through its nominated-substances review process. The agency has not issued a negative finding on Sermorelin. Clinicians and pharmacies should monitor FDA updates, as the nominated-substances process is ongoing [7].

Florida State Law and Sermorelin

Florida Board of Pharmacy Requirements

Florida Statutes Chapter 465 governs pharmacy practice, and Florida Administrative Code Rule 64B16-27 governs sterile compounding [9]. Any Florida pharmacy dispensing injectable Sermorelin must:

• Maintain a Class II Permit for sterile compounding or outsource to a licensed sterile compounder
• Meet USP 797 beyond-use dating and sterility requirements [5]
• Source API only from FDA-registered suppliers
• Conduct end-product potency and sterility testing on each lot

The Florida Department of Health and the Board of Pharmacy conduct routine inspections of sterile compounding facilities. Pharmacies that ship Sermorelin from out of state into Florida must be licensed as non-resident pharmacies under Florida Statute 465.0156 [9].

Florida Medical Practice Act and Prescribing

Florida Statute 458 (for MDs) and 459 (for DOs) require that a valid physician-patient relationship exist before a controlled or compounded drug is prescribed [10]. Sermorelin is not a controlled substance, so prescribing restrictions specific to controlled substances do not apply. Still, the Florida Board of Medicine expects prescribers to document clinical justification, including relevant laboratory data such as IGF-1 levels, and to obtain informed consent.

Advanced practice registered nurses (APRNs) operating under a supervising physician protocol and physician assistants (PAs) under a supervising agreement may also prescribe Sermorelin in Florida under their respective practice acts (Florida Statutes 464 and 458.347) [10].

Telehealth Prescribing in Florida

Florida's Telehealth Act (Florida Statute 456.47) permits licensed Florida health care practitioners to prescribe medications, including compounded drugs, via telehealth after establishing a valid patient-provider relationship [11]. The DEA's 2023 proposed special registration rule for telemedicine prescribing of controlled substances does not affect Sermorelin because it is not scheduled [12]. A Florida telehealth provider may therefore order baseline labs, conduct a video consultation, and prescribe Sermorelin without an in-person visit, provided the clinical standard of care is met.

Clinical Evidence Supporting Medical Use of Sermorelin

Growth Hormone Secretion and IGF-1 Response

Sermorelin's therapeutic rationale rests on its ability to stimulate pulsatile GH release. A randomized double-blind trial published in the Journal of Clinical Endocrinology and Metabolism demonstrated that Sermorelin acetate administered at 0.2 mg subcutaneously each evening significantly increased mean IGF-1 levels compared to placebo in adults with partial GH deficiency (P<0.01) [13]. Pulsatile GH release preserves hypothalamic-pituitary feedback, a physiologic advantage that exogenous recombinant GH does not replicate.

Body Composition Data

A 6-month double-blind trial (N=172) evaluating Sermorelin in older adults found a statistically significant increase in lean body mass and reduction in fat mass compared to placebo [14]. Mean lean body mass increased by approximately 1.5 kg in the Sermorelin group versus 0.3 kg in the placebo group at 26 weeks (P<0.05) [14]. These findings underpin the clinical justification that prescribers in Florida use when ordering the compound.

Sleep and Recovery Endpoints

Sermorelin mimics the nocturnal GH surge that accompanies slow-wave sleep. Administration at bedtime aligns peak drug action with physiologic GH secretory windows, a timing strategy supported by the endocrine principle that GHRH-stimulated GH release is augmented during sleep stages three and four [15].

How to Get Sermorelin Legally in Florida: Step-by-Step

Getting Sermorelin legally requires four steps. Each step has a regulatory checkpoint.

Step 1: Establish Care With a Licensed Florida Prescriber

Choose a Florida-licensed MD, DO, NP, or PA who practices in hormone optimization, endocrinology, or men's or women's health. Telehealth platforms licensed in Florida may satisfy this requirement with a video consultation. The provider must document a clinical indication in the medical record.

Step 2: Complete Required Laboratory Testing

Standard baseline labs before Sermorelin is prescribed include:

• Serum IGF-1 (insulin-like growth factor 1)
• Fasting insulin and glucose (to screen for insulin resistance, which affects GH secretion)
• Complete metabolic panel
• Thyroid function (TSH, free T4), since hypothyroidism blunts GH response [16]
• PSA in men over 40 years old as baseline safety documentation

Low-normal or below-range IGF-1 relative to age-matched reference intervals is the most common laboratory basis for prescribing Sermorelin.

Step 3: Obtain the Prescription From an Accredited Compounding Pharmacy

Your prescriber sends the prescription to a Florida-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility. Ask specifically whether the pharmacy:

• Holds a current Florida sterile compounding permit
• Tests each lot for potency and sterility
• Sources API from an FDA-registered supplier
• Provides a certificate of analysis (COA) for each lot

The four-question checklist above is the HealthRX Compounding Pharmacy Verification Framework. Using it before filling a Sermorelin prescription reduces the likelihood of receiving a subpotent or contaminated preparation. Subpotent compounded peptides are the most common compliance problem cited in FDA warning letters to compounding pharmacies [17].

Step 4: Follow Monitoring Protocol

After starting Sermorelin, clinical follow-up at 90 days with a repeat IGF-1 level is standard practice. The target IGF-1 range is typically the upper quartile of the age-adjusted reference interval, not supraphysiologic levels. Supraphysiologic IGF-1 raises theoretical concerns about cell proliferation, so most prescribers titrate dose to keep IGF-1 within the normal age-matched range [13].

What Is Not Legal: Buying Sermorelin Without a Prescription

Purchasing Sermorelin labeled "for research use only" (RUO) from online peptide vendors and self-injecting it is not legal personal-use medicine. RUO peptides are not manufactured under pharmaceutical current Good Manufacturing Practice (cGMP) standards [17]. The FDA has issued multiple warning letters to companies selling injectable peptides as RUO products when the context makes clear they are intended for human use [17]. In Florida, self-administering a compounded drug without a valid prescription from a Florida-licensed provider violates Florida Statute 465 and potentially constitutes practicing medicine without a license under Florida Statute 458 [10].

Beyond the legal exposure, RUO peptides carry documented quality risks. An FDA analysis of compounded and RUO peptide preparations found that a significant proportion of tested samples contained incorrect active ingredient concentrations, bacterial endotoxins, or undisclosed additives. Using such products negates any benefit the correct molecule might provide and introduces direct harm.

Comparing Sermorelin to Other Peptides in Florida's Regulatory Environment

Not all growth-related peptides share Sermorelin's legal standing. The table below maps key comparisons.

| Peptide | FDA Approval History | Current Compounding Status | Controlled Substance | |---|---|---|---| | Sermorelin | Approved 1990, withdrawn 2008 | Compoundable (no negative finding) | No | | CJC-1295 | Never approved | On FDA 503A negative list as of 2023 | No | | Ipamorelin | Never approved | On FDA 503A negative list as of 2023 | No | | Tesamorelin | Approved (Egrifta, HIV-related lipodystrophy) | Compoundable for approved indication | No | | Somatropin (rGH) | Multiple approvals | Not compoundable from bulk | Schedule III |

The FDA placed CJC-1295 and Ipamorelin on its 503A categorical "do not compound" list in a 2023 guidance update, which represents a material change from prior practice [18]. Sermorelin's distinct regulatory history is a key reason it remains a preferred compounded GHRH-axis peptide for clinicians in Florida.

Frequently Asked Questions